NCT06612827
Recruiting
Not Applicable
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Centre Francois Baclesse1 site in 1 country20 target enrollmentMarch 5, 2025
ConditionsUndifferentiated Carcinoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Undifferentiated Carcinoma
- Sponsor
- Centre Francois Baclesse
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Rate of establishment of exploitable tumor organoids
- Status
- Recruiting
- Last Updated
- 4 months ago
Overview
Brief Summary
The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
- •Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered.
- •Patient with life expectancy greater than 3 months
- •Patient of legal age
- •Patient affiliated to a social security scheme
- •Signature of informed consent prior to any specific study procedure
Exclusion Criteria
- •Persons deprived of their liberty or under guardianship (including curatorship)
- •Pregnant or breast-feeding patient
Outcomes
Primary Outcomes
Rate of establishment of exploitable tumor organoids
Time Frame: through study completion, an average of 3 years
Rate of establishment usable tumor organoids for predictive tests of response to treatment.
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot StudyEndometrial CancerNCT06603506Centre Francois Baclesse16
Terminated
Not Applicable
Organoids From Metastases of Prostate CancerProstatic NeoplasmNCT03952793Centre Antoine Lacassagne1
Completed
Not Applicable
Generation of circulating tumor cell derived organoidsthrough enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancerProstate cancerCRPCHSPCMetastatic prostate cancerNL-OMON29626Eramus Medical Center Rotterdam46
Completed
Not Applicable
Prospective Primary Human Lungcancer Organoids to Predict Treatment ResponseLung CancerNCT04859166Maastricht Radiation Oncology10
Suspended
Not Applicable
Upper GI Serial Tumour BiopsiesOesophageal CancerGastric CancerNCT05233007The Christie NHS Foundation Trust300